Evaluating MRI and blood tests for lung nodules found during cancer screening
A Pilot Study Evaluating the Feasibility of Novel MRI Sequences and Blood-Based Biomarkers for Discriminating Nodules Found During Lung Cancer Screening
Cedars-Sinai Medical Center · NCT05699213
This study is testing how well MRI and blood tests can help people at high risk for lung cancer who have lung nodules found during screening.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Cedars-Sinai Medical Center (other) |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT05699213 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess how well participants are recruited and retained from a centralized lung cancer screening program to support research on MRI and blood-based biomarkers for lung cancer. It focuses on individuals at high risk for lung cancer who have been identified with lung nodules during screening. Participants will undergo lung MRI and blood draws to gather data that may enhance lung cancer screening methods.
Who should consider this trial
Good fit: Ideal candidates are adults aged 50-80 at high risk for lung cancer with lung nodules detected during screening.
Not a fit: Patients with an active diagnosis of cancer or those showing symptoms of lung cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve early detection and monitoring of lung cancer through advanced imaging and biomarker analysis.
How similar studies have performed: Other studies have shown promise in using MRI and biomarkers for lung cancer detection, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability to read and understand informed consent * Male or female adults who are at high risk for lung cancer and are enrolled in the centralized lung cancer screening program: Based on USPSTF guidelines: Age 50-80 with 20 or greater pack-year smoking story who continue to smoke or quit within the past 15 years without sign or symptoms of lung cancer. Or based on National Comprehensive Cancer Network (NCCN) guidelines but do not meet the USPSTF guidelines, age 50-unlimited * Found to have one or more lung nodules that is 6mm or greater on screening LDCT Exclusion Criteria: * Persons with an active diagnosis of cancer * Persons with active signs or symptoms of lung cancer * Persons with mechanically, magnetically, or electrically activated implants, such as cardiac pacemakers, neurostimulators, and infusion pumps. * Persons with ferromagnetic implants and ferromagnetic foreign bodies, such as intracranial aneurysm clips, shrapnel and intraocular metal chips as these could become dislodged. * Persons who are pregnant, nursing, are implanted with intrauterine devices (IUD's) that are not MR-compatible * Persons unable to tolerate MRI imaging secondary to an inability to lie supine or severe claustrophobia. * Persons who are non-compliant with visit instructions, including inability to lie still, hold breath or follow procedure instructions
Where this trial is running
Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California, United States (RECRUITING)
Study contacts
- Principal investigator: Sara Ghandehari, MD — Cedars-Sinai
- Study coordinator: Weijia Chua, MD
- Email: weijia.chua@cshs.org
- Phone: 310-423-1838
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Cancer